8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Feb 26, 2026·SEC
Material company update
Nov 13, 2025·SEC
Fate Therapeutics, Inc.(FATE)Earnings, Financials & Key Ratios
FATE•NASDAQ
Price updated Jun 19, 2026
AboutFate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.Show more
- Revenue$7M-51.2%
- EBITDA-$138M+27.7%
- Net Income-$136M+26.8%
- EPS (Diluted)-1.15+29.9%
- Gross Margin-94.12%-194.1%
- EBITDA Margin-2082.59%-48.4%
- Operating Margin-2222.45%-44.1%
- Net Margin-2051.08%-50.1%
- ROE-51.84%+4.4%
FATE Key Insights
Fate Therapeutics, Inc. (FATE) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 93 (top 7%)
- ✓Trading at only 1.2x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Sales declining 26.7% over 5 years
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when FATE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
FATE Price & Volume
Fate Therapeutics, Inc. (FATE) stock price & volume — 10-year historical chart
Loading chart...
FATE Growth Metrics
Fate Therapeutics, Inc. (FATE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years10.58%
5 Years-26.71%
3 Years-58.98%
TTM-52.64%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM26.14%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM26.85%
Return on Capital
10 Years-42.13%
5 Years-40.42%
3 Years-42.5%
Last Year-43.12%
FATE Recent Earnings
Fate Therapeutics, Inc. (FATE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.26+10.3%
$0.29
Rev
$1M-12.9%
$1M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.27+0.0%
$0.27
Rev
$1M+2.4%
$1M
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.27+6.9%
$0.29
Rev
$2M+45.3%
$1M
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.29+17.1%
$0.35
Rev
$2M+66.0%
$1M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.26vs $0.29+10.3% | $1Mvs $1M-12.9% |
| Q1 2026 | Feb 26, 2026 | $0.27vs $0.27+0.0% | $1Mvs $1M+2.4% |
| Q4 2025 | Nov 13, 2025 | $0.27vs $0.29+6.9% | $2Mvs $1M+45.3% |
| Q3 2025 | Aug 12, 2025 | $0.29vs $0.35+17.1% | $2Mvs $1M+66.0% |
Based on last 12 quarters of dataView full earnings history →
FATE Peer Comparison
Fate Therapeutics, Inc. (FATE) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 EDIT | 263.37M | 2.69 | -1.49 | 25.39% | -281.59% | -6.77% | 2.81 | |
 SANA | 876.62M | 3.15 | -3.28 | -161.87% | 0.49 | |||
 ALNY | 37.1B | 278.09 | 119.35 | 65.19% | 13.46% | 98.29% | 1.62 | |
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 CELC | 4.28B | 87.76 | -23.22 | -244.61% | 1.94 |
Compare FATE vs Peers
Fate Therapeutics, Inc. (FATE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
FATE Income Statement
Fate Therapeutics, Inc. (FATE) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 4.11M | 4.74M | 10.68M | 31.43M | 55.85M | 96.3M | 63.53M | 13.63M | 6.65M | 6.32M |
Revenue Growth % | -6.72% | 15.44% | 125.32% | 194.33% | 77.66% | 72.44% | -34.03% | -78.55% | -51.24% | -52.64% |
Cost of Goods Sold | 34.36M | 56.02M | 0 | 125.62M | 5.85M | 13.76M | 157.19M | 0 | 12.9M | 2.92M |
COGS % of Revenue | 836.78% | 1181.94% | - | 399.64% | 10.48% | 14.29% | 247.41% | - | 194.12% | - |
Gross Profit | -30.25M▲ 0% | -51.28M▼ 69.5% | 10.68M▲ 120.8% | -94.19M▼ 981.9% | 50M▲ 153.1% | 82.54M▲ 65.1% | -93.65M▼ 213.5% | 13.63M▲ 114.6% | -6.25M▼ 145.9% | 3.4M▲ 0% |
Gross Margin % | -736.78% | -1081.94% | 100% | -299.64% | 89.52% | 85.71% | -147.41% | 100% | -94.12% | 53.8% |
Gross Profit Growth % | -37.2% | -69.52% | 120.83% | -981.92% | 153.08% | 65.1% | -213.46% | 114.55% | -145.89% | - |
Operating Expenses | 46.23M | 71.83M | 111.41M | 33.9M | 266.99M | 390.93M | 96.86M | 223.91M | 141.45M | 142.82M |
OpEx % of Revenue | 1125.94% | 1515.44% | 1043.14% | 107.83% | 478.08% | 405.95% | 152.45% | 1642.63% | 2128.33% | - |
Selling, General & Admin | 11.87M | 15.81M | 23.64M | 33.9M | 57.32M | 84.23M | 96.86M | 74.17M | 46.52M | 42.34M |
SG&A % of Revenue | 289.16% | 333.5% | 221.32% | 107.83% | 102.64% | 87.47% | 152.45% | 544.12% | 699.99% | - |
Research & Development | 34.36M | 56.02M | 87.77M | 125.62M | 215.52M | 320.45M | 172.6M | 135M | 107.83M | 100.48M |
R&D % of Revenue | 836.78% | 1181.94% | 821.82% | 399.64% | 385.92% | 332.77% | 271.66% | 990.4% | 1622.46% | - |
Other Operating Expenses | 0 | 0 | 0 | -125.62M | -5.85M | -13.76M | -172.6M | 14.74M | -12.9M | 0 |
Operating Income | -42.13M▲ 0% | -67.09M▼ 59.3% | -100.73M▼ 50.1% | -128.09M▼ 27.2% | -216.99M▼ 69.4% | -308.39M▼ 42.1% | -190.51M▲ 38.2% | -210.28M▼ 10.4% | -147.7M▲ 29.8% | -139.42M▲ 0% |
Operating Margin % | -1025.94% | -1415.44% | -943.14% | -407.47% | -388.56% | -320.23% | -299.86% | -1542.63% | -2222.45% | -2207.47% |
Operating Income Growth % | -31.79% | -59.27% | -50.13% | -27.16% | -69.41% | -42.12% | 38.22% | -10.37% | 29.76% | - |
EBITDA | -41.15M | -65.89M | -98.53M | -125M | -211.14M | -294.63M | -172.23M | -191.31M | -138.41M | -126.94M |
EBITDA Margin % | -1002.29% | -1390.04% | -922.6% | -397.65% | -378.08% | -305.95% | -271.09% | -1403.52% | -2082.59% | -2009.78% |
EBITDA Growth % | -32.4% | -60.1% | -49.55% | -26.86% | -68.92% | -39.54% | 41.54% | -11.08% | 27.65% | 30.64% |
D&A (Non-Cash Add-back) | 971K | 1.2M | 2.19M | 3.09M | 5.85M | 13.76M | 18.28M | 18.96M | 9.29M | 12.49M |
EBIT | -41.68M | -64.9M | -96.4M | -128.09M | -216.99M | -308.39M | -190.51M | -195.54M | -136.31M | -134.04M |
Net Interest Income | -709K | 494K | 2.58M | 2.4M | 1.31M | 5.84M | 17.19M | 17.29M | 11.05M | 9.58M |
Interest Income | 559K | 2.19M | 4.33M | 2.4M | 1.31M | 5.84M | 17.19M | 17.29M | 11.05M | 9.58M |
Interest Expense | 1.27M | 1.7M | 1.75M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | -827K | 494K | 2.58M | -45.3M | 4.84M | 26.66M | 29.58M | 24.01M | 11.39M | 9.52M |
Pretax Income | -42.95M▲ 0% | -66.6M▼ 55.1% | -98.15M▼ 47.4% | -173.39M▼ 76.7% | -212.15M▼ 22.4% | -281.72M▼ 32.8% | -160.93M▲ 42.9% | -186.26M▼ 15.7% | -136.31M▲ 26.8% | -129.91M▲ 0% |
Pretax Margin % | -1046.08% | -1405.02% | -919% | -551.59% | -379.89% | -292.55% | -253.3% | -1366.46% | -2051.08% | -2056.79% |
Income Tax | 297K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | -0.69% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -42.95M▲ 0% | -66.6M▼ 55.1% | -98.15M▼ 47.4% | -173.39M▼ 76.7% | -212.15M▼ 22.4% | -281.72M▼ 32.8% | -160.93M▲ 42.9% | -186.26M▼ 15.7% | -136.31M▲ 26.8% | -129.91M▲ 0% |
Net Margin % | -1046.08% | -1405.02% | -919% | -551.59% | -379.89% | -292.55% | -253.3% | -1366.46% | -2051.08% | -2056.79% |
Net Income Growth % | -28.36% | -55.05% | -47.38% | -76.66% | -22.36% | -32.79% | 42.88% | -15.74% | 26.82% | 26.14% |
Net Income (Continuing) | -42.95M | -66.6M | -98.15M | -173.39M | -212.15M | -281.72M | -160.93M | -186.26M | -136.31M | -129.91M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.02▲ 0% | -1.19▼ 16.7% | -1.43▼ 20.2% | -2.10▼ 46.9% | -2.24▼ 6.7% | -2.91▼ 29.9% | -1.64▲ 43.6% | -1.64▲ 0.0% | -1.15▲ 29.9% | -1.08▲ 0% |
EPS Growth % | 2.86% | -16.67% | -20.17% | -46.85% | -6.67% | -29.91% | 43.64% | 0% | 29.88% | 26.85% |
EPS (Basic) | -1.02 | -1.19 | -1.43 | -2.10 | -2.24 | -2.91 | -1.64 | -1.64 | -1.15 | - |
Diluted Shares Outstanding | 41.98M | 56.2M | 68.19M | 82.39M | 94.75M | 96.83M | 98.41M | 113.69M | 118.79M | 120.03M |
Basic Shares Outstanding | 41.98M | 56.2M | 68.19M | 82.39M | 94.75M | 96.83M | 98.41M | 113.69M | 118.79M | 120.03M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
FATE Balance Sheet
Fate Therapeutics, Inc. (FATE) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 102.6M | 205.2M | 227.09M | 494.32M | 633.41M | 502.07M | 331.54M | 291.91M | 208.7M | 179.53M |
Cash & Short-Term Investments | 100.95M | 201.01M | 221.43M | 482.92M | 615.91M | 436.23M | 315.18M | 279.07M | 203.66M | 174.82M |
Cash Only | 88.95M | 190.51M | 99.81M | 167.35M | 133.58M | 61.33M | 41.87M | 36.06M | 46.63M | 39.57M |
Short-Term Investments | 12M | 10.49M | 121.61M | 315.57M | 482.33M | 374.89M | 273.31M | 243.01M | 157.03M | 135.25M |
Accounts Receivable | 0 | 500K | 0 | 5.51M | 8.68M | 38.48M | 1.83M | 3.54M | 916K | 704K |
Days Sales Outstanding | - | 38.5 | - | 64.04 | 56.7 | 145.85 | 10.49 | 94.76 | 50.31 | 53.41 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 1.65M | 0 | 5.66M | 5.89M | 0 | 27.37M | 900K | 9.3M | 4.13M | 4M |
Total Non-Current Assets | 2.7M | 7.84M | 75.19M | 128.13M | 288.04M | 203.49M | 174.68M | 148.78M | 110.23M | 105.39M |
Property, Plant & Equipment | 2.55M | 5.13M | 22.75M | 99.39M | 162.25M | 66.07M | 158.51M | 110.89M | 98.53M | 95.34M |
Fixed Asset Turnover | 1.61x | 0.92x | 0.47x | 0.32x | 0.34x | 1.46x | 0.40x | 0.12x | 0.07x | 0.06x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 122K | 2.19M | 39.44M | 28.73M | 100.66M | 4.94M | 980K | 27.66M | 1.47M | 37.87M |
Other Non-Current Assets | 24K | 526K | 12.99M | 9K | 25.13M | 132.48M | 15.19M | 10.24M | 10.23M | 10.05M |
Total Assets | 105.29M▲ 0% | 213.03M▲ 102.3% | 302.27M▲ 41.9% | 622.46M▲ 105.9% | 921.46M▲ 48.0% | 705.56M▼ 23.4% | 506.22M▼ 28.3% | 440.69M▼ 12.9% | 318.94M▼ 27.6% | 284.92M▲ 0% |
Asset Turnover | 0.04x | 0.02x | 0.04x | 0.05x | 0.06x | 0.14x | 0.13x | 0.03x | 0.02x | 0.02x |
Asset Growth % | 10.78% | 102.33% | 41.89% | 105.92% | 48.04% | -23.43% | -28.25% | -12.94% | -27.63% | -116.45% |
Total Current Liabilities | 11.05M | 27.26M | 27.81M | 85.56M | 81.28M | 114.05M | 39.09M | 38.52M | 36.07M | 30.69M |
Accounts Payable | 1.68M | 4.21M | 5.82M | 6.28M | 8.61M | 8.27M | 4.72M | 9.37M | 2.66M | 3.28M |
Days Payables Outstanding | 17.83 | 27.4 | - | 18.26 | 537.33 | 219.27 | 10.96 | - | 75.14 | 421.44 |
Short-Term Debt | 0 | 2.44M | 0 | 3.35M | 0 | 0 | 0 | 0 | 4.56M | 4.74M |
Deferred Revenue (Current) | 2.1M | 7.59M | 2.79M | 21.14M | 21.48M | 42.23M | 0 | 393K | 381K | 968K |
Other Current Liabilities | 5.5M | 10.09M | 12.18M | 49.97M | 3.2M | 40.03M | 685K | 11.64M | 28.47M | 22.09M |
Current Ratio | 9.29x | 7.53x | 8.17x | 5.78x | 7.79x | 4.40x | 8.48x | 7.58x | 5.79x | 5.85x |
Quick Ratio | 9.29x | 7.53x | 8.17x | 5.78x | 7.79x | 4.40x | 8.48x | 7.58x | 5.79x | 5.85x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -368.03 |
Total Non-Current Liabilities | 17.05M | 25.3M | 29.71M | 152.45M | 161.33M | 107.57M | 98.71M | 83.45M | 75.68M | 74.52M |
Long-Term Debt | 14.81M | 12.45M | 0 | 0 | 0 | 0 | 0 | 0 | 73.29M | 72.05M |
Capital Lease Obligations | 0 | 0 | 25.23M | 93.94M | 109.24M | 103.71M | 97.36M | 77.85M | 0 | 150.17M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1.52M | 5.35M | 702K | 12.48M | 24.97M | 3.86M | 1.35M | 5.6M | 2.4M | 2.48M |
Total Liabilities | 28.1M | 52.56M | 57.52M | 238.01M | 242.62M | 221.62M | 137.8M | 121.97M | 111.75M | 105.21M |
Total Debt | 14.81M | 14.88M | 26.93M | 97.3M | 114.82M | 109.34M | 103.54M | 85.27M | 77.85M | 76.78M |
Net Debt | -74.14M | -175.63M | -72.89M | -70.05M | -18.77M | 48.01M | 61.67M | 49.21M | 31.22M | 37.22M |
Debt / Equity | 0.19x | 0.09x | 0.11x | 0.25x | 0.17x | 0.23x | 0.28x | 0.27x | 0.38x | 0.43x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.60x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.29x |
Interest Coverage | -32.87x | -38.27x | -55.02x | - | - | - | - | - | - | - |
Total Equity | 77.19M▲ 0% | 160.47M▲ 107.9% | 244.76M▲ 52.5% | 384.44M▲ 57.1% | 678.84M▲ 76.6% | 483.94M▼ 28.7% | 368.42M▼ 23.9% | 318.73M▼ 13.5% | 207.18M▼ 35.0% | 179.71M▲ 0% |
Equity Growth % | 5.52% | 107.89% | 52.53% | 57.07% | 76.58% | -28.71% | -23.87% | -13.49% | -35% | -142.25% |
Book Value per Share | 1.84 | 2.86 | 3.59 | 4.67 | 7.16 | 5.00 | 3.74 | 2.80 | 1.74 | 1.50 |
Total Shareholders' Equity | 77.19M | 160.47M | 244.76M | 384.44M | 678.84M | 483.94M | 368.42M | 318.73M | 207.18M | 179.71M |
Common Stock | 53K | 65K | 76K | 88K | 96K | 97K | 99K | 114K | 115K | 116K |
Retained Earnings | -218.8M | -285.4M | -383.55M | -556.93M | -769.08M | -1.05B | -1.21B | -1.4B | -1.53B | -1.57B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -3K | -2K | 22K | 70K | -762K | -1.85M | 15K | 268K | 116K | -77K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
FATE Cash Flow Statement
Fate Therapeutics, Inc. (FATE) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -36.91M | -38.65M | -83.17M | -39.23M | -162.87M | -248.21M | -132.26M | -122.87M | -106.08M | -103.1M |
Operating CF Margin % | -898.81% | -815.4% | -778.79% | -124.8% | -291.64% | -257.74% | -208.18% | -901.43% | -1596.21% | - |
Operating CF Growth % | -23.75% | -4.73% | -115.2% | 52.84% | -315.18% | -52.4% | 46.71% | 7.1% | 13.66% | 66.01% |
Net Income | -42.95M | -66.6M | -98.15M | -173.39M | -212.15M | -281.72M | -160.93M | -186.26M | -136.31M | -129.91M |
Depreciation & Amortization | 971K | 1.2M | 2.19M | 3.09M | 5.85M | 13.76M | 18.28M | 18.96M | 9.29M | 4.86M |
Stock-Based Compensation | 3.61M | 6.29M | 17.41M | 30.75M | 54.36M | 78.73M | 43.46M | 41.5M | 24.92M | 15.94M |
Deferred Taxes | 5K | -335K | -478K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -613K | 19.04M | -7.79M | 113.09M | -13.03M | -24.27M | -52.26M | 4.89M | -247K | -22.03M |
Working Capital Changes | 2.08M | 1.74M | 3.64M | -12.77M | 2.1M | -34.71M | 19.18M | -1.96M | -3.74M | -4.33M |
Change in Receivables | 0 | -500K | 500K | -5.51M | -3.16M | -29.8M | 36.65M | -1.11M | 2.62M | 1.7M |
Change in Inventory | 0 | -4.25M | -4.28M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 2.51M | 4.25M | 4.28M | -1.55M | 0 | 14.25M | -28.94M | -1.66M | -9.03M | -4.91M |
Cash from Investing | -10.2M | -463K | -157.45M | -161.08M | -324.02M | 166.75M | 112.67M | 12.22M | 111.17M | 92.08M |
Capital Expenditures | -1.73M | -2.3M | -7.39M | -4.93M | -50.7M | -35.57M | -6.15M | -730K | -5.95M | -5M |
CapEx % of Revenue | 42.01% | 48.59% | 69.24% | 15.69% | 90.79% | 36.93% | 9.68% | 5.36% | 89.57% | 79.1% |
Acquisitions | 0 | 0 | 150.06M | 0 | 0 | 0 | 0 | 0 | 362K | -122K |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -8.47M | 1.84M | -150.06M | 0 | 0 | 0 | 0 | 0 | 0 | 484K |
Cash from Financing | 47.44M | 140.78M | 149.93M | 282.84M | 453.13M | 9.21M | 85K | 99.89M | 5.49M | 5.49M |
Debt Issued (Net) | 4.15M | 0 | -15M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 43.01M | 134.58M | 162.41M | 282.35M | 411.74M | 9.21M | 85K | 94.82M | 0 | 0 |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 283K | 6.2M | 2.52M | 490K | 41.39M | 0 | 0 | 5.07M | 5.49M | 5.49M |
Net Change in Cash | 343K▲ 0% | 101.67M▲ 29540.5% | -90.7M▼ 189.2% | 67.53M▲ 174.5% | -33.76M▼ 150.0% | -72.25M▼ 114.0% | -19.46M▲ 73.1% | -5.81M▲ 70.1% | 10.57M▲ 281.8% | -5.53M▲ 0% |
Free Cash Flow | -38.63M▲ 0% | -40.95M▼ 6.0% | -90.57M▼ 121.2% | -44.16M▲ 51.2% | -213.57M▼ 383.6% | -283.77M▼ 32.9% | -138.42M▲ 51.2% | -123.6M▲ 10.7% | -112.04M▲ 9.4% | -108.09M▲ 0% |
FCF Margin % | -940.82% | -863.99% | -848.03% | -140.49% | -382.43% | -294.68% | -217.86% | -906.79% | -1685.78% | -1711.42% |
FCF Growth % | -27.58% | -6.01% | -121.16% | 51.24% | -383.63% | -32.87% | 51.22% | 10.7% | 9.36% | 13.65% |
FCF per Share | -0.92 | -0.73 | -1.33 | -0.54 | -2.25 | -2.93 | -1.41 | -1.09 | -0.94 | -0.90 |
FCF Conversion (FCF/Net Income) | 0.86x | 0.58x | 0.85x | 0.23x | 0.77x | 0.88x | 0.82x | 0.66x | 0.78x | 0.83x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
FATE Key Ratios
Fate Therapeutics, Inc. (FATE) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -57.14% | -56.05% | -48.44% | -55.11% | -39.9% | -48.46% | -37.76% | -54.21% | -51.84% | -58.89% |
Return on Invested Capital (ROIC) | -1037.56% | - | -96.42% | -39.51% | -33.4% | -38.81% | -29.7% | -39.52% | -36.54% | -40.63% |
Gross Margin | -736.78% | -1081.94% | 100% | -299.64% | 89.52% | 85.71% | -147.41% | 100% | -94.12% | 53.8% |
Net Margin | -1046.08% | -1405.02% | -919% | -551.59% | -379.89% | -292.55% | -253.3% | -1366.46% | -2051.08% | -2056.79% |
Debt / Equity | 0.19x | 0.09x | 0.11x | 0.25x | 0.17x | 0.23x | 0.28x | 0.27x | 0.38x | 0.43x |
Interest Coverage | -32.87x | -38.27x | -55.02x | - | - | - | - | - | - | - |
FCF Conversion | 0.86x | 0.58x | 0.85x | 0.23x | 0.77x | 0.88x | 0.82x | 0.66x | 0.78x | 0.83x |
Revenue Growth | -6.72% | 15.44% | 125.32% | 194.33% | 77.66% | 72.44% | -34.03% | -78.55% | -51.24% | -52.64% |
Related:FATE Dividend History·FATE Revenue History·FATE Price History·FATE P/E History·FATE Financial Ratios·FATE Institutional Holders
FATE SEC Filings & Documents
Fate Therapeutics, Inc. (FATE) SEC filings — annual & quarterly reports (10-K, 10-Q)
FATE Frequently Asked Questions
Fate Therapeutics, Inc. (FATE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Fate Therapeutics, Inc. (FATE) reported $6.3M in revenue for fiscal year 2025. This represents a 440% increase from $1.2M in 2011.
Fate Therapeutics, Inc. (FATE) saw revenue decline by 51.2% over the past year.
Fate Therapeutics, Inc. (FATE) reported a net loss of $129.9M for fiscal year 2025.
Dividend & Returns
Fate Therapeutics, Inc. (FATE) has a return on equity (ROE) of -51.8%. Negative ROE indicates the company is unprofitable.
Fate Therapeutics, Inc. (FATE) had negative free cash flow of $108.1M in fiscal year 2025, likely due to heavy capital investments.